Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.

Seeley, Todd W; Sternlicht, Mark D; Klaus, Stephen J; Neff, Thomas B; Liu, David Y

Seeley, Todd W; Sternlicht, Mark D; Klaus, Stephen J; Neff, Thomas B; Liu, David Y.

Afiliação

Seeley TW; Therapeutics R&D, FibroGen, Inc., San Francisco, CA, USA.
Sternlicht MD; Therapeutics R&D, FibroGen, Inc., San Francisco, CA, USA.
Klaus SJ; Therapeutics R&D, FibroGen, Inc., San Francisco, CA, USA.
Neff TB; Therapeutics R&D, FibroGen, Inc., San Francisco, CA, USA.
Liu DY; Therapeutics R&D, FibroGen, Inc., San Francisco, CA, USA.

Hypoxia (Auckl) ; 5: 1-9, 2017.

Article em En | MEDLINE | ID: mdl-28331872

Palavras-chave

MMTV-Neu breast cancer model; cancer progression; erythropoiesis; hypoxia-inducible factor; hypoxia-inducible factor prolyl hydroxylase inhibitors; vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017